ARGENTA DISCOVERY AND TTP LABTECH ANNOUNCE HIGH CONTENT SCREENING AND DRUG DISCOVERY COLLABORATION
|
|
|
29 January 2004 |
The Acumen Explorer is a laser scanning fluorescence microplate cytometer that enables the development and execution of powerful cell-based high content screens. The implementation of TTP LabTech’s Acumen Explorer will expand Argenta’s already comprehensive drug discovery offering and strengthen its position as a high quality provider of research services to the pharmaceutical industry.
In addition, Argenta and TTP LabTech have agreed a collaboration to develop novel assays to accelerate the drug discovery process, as an offering to the pharmaceutical industry to support Argenta’s internal research programs. This collaboration will take advantage of TTP LabTech’s proven track record in developing cutting edge assay technology and Argenta’s expertise in drug screening and eADMET.
“Argenta is committed to staying at the forefront of drug discovery and the implementation of industry leading technologies are key to achieving this goal. With the incorporation of the Explorer technology, Argenta has further strengthened its biology services capability and has taken a major step towards becoming a leader in High-Content Screening” said Dr. Peter Lockey, Argenta’s Director of Biology. “TTP LabTech is widely recognised as a high quality provider of screening technology and Argenta is delighted to be working with them.”
“Combining the Acumen Explorer microplate cytometer with Argenta’s assay development and screening expertise will enable extensive assessment of both cell and biological processes central to drug discovery.” added Dr. Wayne Bowen, Chief Scientific Officer of TTP LabTech Ltd.
Editors’ notes
About Argenta Discovery
Argenta Discovery is an independent discovery company providing peer quality contract services in medicinal chemistry and biochemistry to pharmaceutical companies of all sizes. Argenta draws on its industry experienced scientists to rapidly deliver hit finding capabilities together with the ability to convert and optimize hits and leads into validated, patentable chemical lead series and potential drug candidates. The company has previously worked with or is currently working with Aventis, Pharmagene, Millennium, Adolor, De Novo, GlaxoSmithKline, Lundbeck, Amedis and other undisclosed partners. Argenta also actively works on its own research projects and can source targets via a unique relationship with London’s Imperial College School of Medicine (Europe’s largest medical school). Patentable lead series resulting from in-house programs will be available for sale or license.
Argenta operates in new, state of the art laboratories in Harlow, UK, and is served by nearby London Stansted Airport. The company also has commercial offices in the US and Japan, reflecting its global client base. Its scientific skills include computer-aided drug design, medicinal, parallel and combinatorial chemistry, high throughput analytical chemistry, molecular biology, biochemical assay development, automated molecular and cellular screening and in vitro ADMET screening. For further information please see www.argentadiscovery.com or email info@argentadiscovery.com.
About TTP LabTech Ltd
TTP LabTech is part of TTP Group plc, one of the world’s most successful technology companies. Since its formation, TTP Group has incubated businesses with a combined turnover of £95M in 2002.TTP LabTech combines the best science with first-rate engineering to increase efficiency, effectiveness, flexibility or overall capability in key biopharmaceutical research processes.
In July 2003, TTP LabTech merged with Acumen Bioscience (another TTP Group company) adding the Explorer™ fluorescence microplate reader to its range of products covering compound storage, low volume liquid handling and fluorescence detection.
For more information:
Product enquiries
Ian Whitehall, TTP LabTech Limited
Tel +44 (0)1763 262626 Email sales@ttplabtech.com
Media enquiries
David Robinson, Alto Marketing Limited
Tel +44 (0)1489 557672 Email davidr@alto-marketing.com
